Celyad SA (CYAD)

After Hours
- Real-time Data
  • Volume:
  • Bid/Ask:
  • Day's Range:
    4.270 - 4.400

CYAD Overview

Prev. Close
Day's Range
52 wk Range
Market Cap
Dividend (Yield)
Average Vol. (3m)
P/E Ratio
1-Year Change
Shares Outstanding
Next Earnings Date
Nov 10, 2021
What is your sentiment on Celyad SA?
Market is currently closed. Voting is open during market hours.

Celyad SA News

  • FDA to beef up cell and gene therapy staff
    • BySeeking Alpha-

    Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott...

  • Key events next week - healthcare
    • BySeeking Alpha-

    Noteworthy events during the week of November 25 - December 1 for healthcare investors. MONDAY (11/26): FDA action date for Loxo Oncology's (NASDAQ:LOXO) larotrectinib in NTRK...

Celyad SA Analysis

Technical Summary

5 Min
15 Min
Moving AveragesStrong BuyStrong BuyStrong BuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuySellStrong Sell
SummaryStrong BuyStrong BuyStrong BuySellStrong Sell

Celyad SA Company Profile

Celyad SA Company Profile


Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company’s preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Read More
  • Let's go until 15
    • They report Phase 1 results on July 5th, 2019.
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.